Teva Pharmaceutical Industries Limited - Product Pipeline Review - 2015

Published: Apr, 2015 | Pages: 141 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Teva Pharmaceutical Industries Limited - Product Pipeline Review - 2015

Summary 

Global Markets Direct's, 'Teva Pharmaceutical Industries Limited - Product Pipeline Review - 2015', provides an overview of the Teva Pharmaceutical Industries Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Teva Pharmaceutical Industries Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Teva Pharmaceutical Industries Limited including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Teva Pharmaceutical Industries Limited's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Teva Pharmaceutical Industries Limited's pipeline products

Reason To Buy 

- Evaluate Teva Pharmaceutical Industries Limited's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Teva Pharmaceutical Industries Limited in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Teva Pharmaceutical Industries Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Teva Pharmaceutical Industries Limited and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Teva Pharmaceutical Industries Limited
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Teva Pharmaceutical Industries Limited and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Teva Pharmaceutical Industries Limited Snapshot 6
Teva Pharmaceutical Industries Limited Overview 6
Key Information 6
Key Facts 6
Teva Pharmaceutical Industries Limited - Research and Development Overview 7
Key Therapeutic Areas 7
kTeva Pharmaceutical Industries Limited - Pipeline Review 11
Teva Pharmaceutical Industries Limited - Pipeline Review 12
Pipeline Products by Stage of Development 12
Pipeline Products - Monotherapy 13
Pipeline Products - Combination Treatment Modalities 14
Pipeline Products - Partnered Products 15
Pipeline Products - Out-Licensed Products 17
Teva Pharmaceutical Industries Limited - Pipeline Products Glance 19
Teva Pharmaceutical Industries Limited - Late Stage Pipeline Products 19
Teva Pharmaceutical Industries Limited - Clinical Stage Pipeline Products 22
Teva Pharmaceutical Industries Limited - Early Stage Pipeline Products 24
Teva Pharmaceutical Industries Limited - Unknown Stage Pipeline Products 26
Teva Pharmaceutical Industries Limited - Drug Profiles 27
(ethinylestradiol + levonorgestrel) 27
glatiramer acetate 28
hydrocodone bitartrate ER 30
laquinimod sodium 32
lipegfilgrastim 36
(fluticasone propionate + salmeterol xinafoate) 37
albutropin 38
armodafinil 39
beclomethasone dipropionate 41
bendamustine hydrochloride 43
fluticasone propionate 46
pridopidine hydrochloride 47
rasagiline mesylate 49
reslizumab 50
omacetaxine mepesuccinate 51
TEV-48125 54
TV-1380 56
TV-45070 57
atropine sulfate 58
CEP-37250 59
CEP-37440 60
irdabisant 61
TEV-90110 62
TEV-90112 63
TV-46017 64
TV-46139 65
TV-46763 66
TV-48108 67
CEP-11981 68
CEP-28122 69
CEP-33779 70
Drug for Undisclosed Indication 71
MDT-011 72
MetPril 73
modafinil next generation 74
NP-201 75
NP-202 76
Recombinant Protein to Inhibit IL-17A for Psoriasis 77
Recombinant Protein to Target CD38 for Multiple Myeloma 78
Small Molecule-2 to Antagonize 5-HT6 for CNS Disorders 79
(acetaminophen + immediate release opioid 1) 80
(acetaminophen + immediate release opioid 2) 81
AD-3 82
AD-4 83
Fixed Dose Combination-3 for HIV 84
Fixed Dose Combination-4 for HIV 85
risperidone LAI 86
Small Molecule to Inhibit Poly (ADP-Ribose) Polymerase 1 for Undisclosed Indication 87
Small Molecule-1 to Antagonize 5-HT6 Receptor for CNS Disorders 88
Drug for Dependence 89
Drug For Parkinson Disease 90
Teva Pharmaceutical Industries Limited - Pipeline Analysis 91
Teva Pharmaceutical Industries Limited - Pipeline Products by Target 91
Teva Pharmaceutical Industries Limited - Pipeline Products by Route of Administration 94
Teva Pharmaceutical Industries Limited - Pipeline Products by Molecule Type 95
Teva Pharmaceutical Industries Limited - Pipeline Products by Mechanism of Action 96
Teva Pharmaceutical Industries Limited - Recent Pipeline Updates 99
Teva Pharmaceutical Industries Limited - Dormant Projects 118
Teva Pharmaceutical Industries Limited - Discontinued Pipeline Products 121
Discontinued Pipeline Product Profiles 121
Teva Pharmaceutical Industries Limited - Company Statement 125
Teva Pharmaceutical Industries Limited - Locations And Subsidiaries 127
Head Office 127
Other Locations & Subsidiaries 127
Appendix 136
Methodology 136
Coverage 136
Secondary Research 136
Primary Research 136
Expert Panel Validation 136
Contact Us 136
Disclaimer 137

List of Tables

Teva Pharmaceutical Industries Limited, Key Information 10
Teva Pharmaceutical Industries Limited, Key Facts 10
Teva Pharmaceutical Industries Limited - Pipeline by Indication, 2015 13
Teva Pharmaceutical Industries Limited - Pipeline by Stage of Development, 2015 16
Teva Pharmaceutical Industries Limited - Monotherapy Products in Pipeline, 2015 17
Teva Pharmaceutical Industries Limited - Combination Treatment Modalities in Pipeline, 2015 18
Teva Pharmaceutical Industries Limited - Partnered Products in Pipeline, 2015 19
Teva Pharmaceutical Industries Limited - Partnered Products/ Combination Treatment Modalities, 2015 20
Teva Pharmaceutical Industries Limited - Out-Licensed Products in Pipeline, 2015 21
Teva Pharmaceutical Industries Limited - Out-Licensed Products/ Combination Treatment Modalities, 2015 22
Teva Pharmaceutical Industries Limited - Pre-Registration, 2015 23
Teva Pharmaceutical Industries Limited - Filing rejected/Withdrawn, 2015 24
Teva Pharmaceutical Industries Limited - Phase III, 2015 25
Teva Pharmaceutical Industries Limited - Phase II, 2015 26
Teva Pharmaceutical Industries Limited - Phase I, 2015 27
Teva Pharmaceutical Industries Limited - Preclinical, 2015 28
Teva Pharmaceutical Industries Limited - Discovery, 2015 29
Teva Pharmaceutical Industries Limited - Unknown, 2015 30
Teva Pharmaceutical Industries Limited - Pipeline by Target, 2015 96
Teva Pharmaceutical Industries Limited - Pipeline by Route of Administration, 2015 98
Teva Pharmaceutical Industries Limited - Pipeline by Molecule Type, 2015 99
Teva Pharmaceutical Industries Limited - Pipeline Products by Mechanism of Action, 2015 101
Teva Pharmaceutical Industries Limited - Recent Pipeline Updates, 2015 103
Teva Pharmaceutical Industries Limited - Dormant Developmental Projects,2015 122
Teva Pharmaceutical Industries Limited - Discontinued Pipeline Products, 2015 125
Teva Pharmaceutical Industries Limited, Other Locations 131
Teva Pharmaceutical Industries Limited, Subsidiaries 132